Loading...
•
Apr 02, 2021
Enovis Q1 2021 Earnings Report
Reported an increase in sales and adjusted EPS, driven by strong performance in both ESAB and MedTech segments.
Key Takeaways
Colfax Corporation reported strong first-quarter results with an 8% increase in sales and a 16% rise in adjusted EPS. The company's performance was driven by increased demand and margin expansion in ESAB, as well as improved market conditions and share gains in the MedTech segment. Colfax is raising the low-end of its adjusted 2021 EPS guidance range to $2.05-$2.15.
Reported $0.19 EPS from continuing operations and achieved $0.44 of adjusted EPS.
Grew sales 8% including organic sales-per-day growth of 9%.
Announced expanded fast-growing foot & ankle business with the acquisition of MedShape.
Raising low-end of adjusted 2021 EPS guidance range to $2.05-$2.15.
Enovis
Enovis
Forward Guidance
For the second quarter of 2021, Colfax expects adjusted earnings of $0.48 to $0.53 per diluted share. This guidance range reflects the recent equity issuance and senior note redemptions.